Delivery Order SPE2DB22D1106-SPE2DB24FFER8

Award Date 7/30/24
Potential Completion Date 7/31/24
Potential Value $21K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the provision of Gardasil 9 syringes, a vaccine for the prevention of certain types of human papillomavirus (HPV). The $34,423.12 firm-fixed-price contract has a completion date of June 25, 2024. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that has established itself as a key vendor for federal healthcare programs,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,449.83, is for the delivery of Gardasil 9 syringes, a vaccine for the prevention of certain types of human papillomavirus (HPV). The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 21, 2025. The contract is not set aside and was awarded on an open...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Gardasil 9 syringes, a vaccine used to prevent certain types of human papillomavirus (HPV). The contract has a ceiling value of $38,497.65 and a period of performance ending on April 17, 2025. It is a firm-fixed-price contract, indicating a pre-determined price for the goods. The...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $42,366.96 contract is for the supply of GARDASIL 9 syringes, a vaccine product, with a period of performance through May 2025. The award is not a set-aside contract, indicating open competition. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $29,691.79 firm-fixed-price contract is for the supply of Gardasil 9 syringes, a vaccine product. The contract has an ultimate completion date of December 5, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with DLA Troop Support...
This is a delivery order awarded to Amerisourcebergen Drug Corp under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The order is for 4,565,179 units of the GARDASIL 9 vaccine, a pharmaceutical product used to prevent certain types of human papillomavirus (HPV) infections. The delivery order has a ceiling value of $8,857.24 and a firm fixed-price pricing structure. It has a period of performance through July 18, 2024. This contract...
This is a $17,474.60 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for GARDASIL 9 syringes, a vaccine product. The contract has an ultimate completion date of June 10, 2025 and is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,989.84 fixed-price delivery order is for the supply of GARDASIL 9 syringes, a vaccine for the prevention of certain types of human papillomavirus (HPV). The contract has an ultimate completion date of January 30, 2025 and is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite...
This is a $19,782.56 firm-fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of GARDASIL 9 syringes, a vaccine product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999, which enables the DLA to efficiently procure a wide range of medical commodities from AmerisourceBergen to support...
This is a delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $8,902.47 firm-fixed-price contract is for the delivery of GARDASIL 9 syringes, a human papillomavirus vaccine, to support military healthcare programs. The contract is not designated as a set-aside and is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FFER8
    Delivery Order

This is a $21,088.73 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of Gardasil 9, a vaccine for the prevention of certain types of human papillomavirus (HPV), with an ultimate completion date of July 31, 2024. The award is not associated with a set-aside program. AmerisourceBergen has been awarded multiple Indefinite Delivery Contracts (IDCs) by the DLA and other federal agencies, such as the Department of Justice Federal Bureau of Investigation, to provide a wide range of pharmaceutical and medical supplies to support the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 10/29/24, 9:04 AM